COMMUNIQUÉS West-GlobeNewswire

Praxis Precision Medicines to Participate in Upcoming April Conferences
05/04/2024
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer
05/04/2024
FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
05/04/2024
Marks major milestone prior to launch in U.S. market PressureSafe ™ s canner and disposable pack both listed with FDA PressureSafe ™ can support early detection of pressure injuries, potentially setting a new standard [...]
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
05/04/2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a [...]
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
05/04/2024
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today [...]
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
05/04/2024
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026 NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage [...]
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
05/04/2024
New development pathway significantly expands addressable patient population for IV Choline Chloride IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN [...]
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05/04/2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/04/2024
DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe [...]
ORYZON to Provide Corporate Progress Updates at Several Events in April
05/04/2024
Investing in Oncology Forum 2024 Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024 LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
05/04/2024
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions [...]
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
05/04/2024
TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive /Experienced patients in ongoing NMIBC program TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only [...]
Postponement Annual Shareholders Meeting - Amendment financial calendar
05/04/2024
Postponement Annual Shareholders Meeting - Amendment financial calendar Leuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today [...]
Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry
05/04/2024
– Financing will support development of a foundational machine learning model of medicinal chemistry that can accurately predict small molecule drug candidates for any protein – – Releases unprecedented dataset publicly [...]
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
05/04/2024
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/04/2024
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
05/04/2024
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE [...]
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
05/04/2024
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the [...]
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
05/04/2024
Company presentation and fireside chat on April 11th at 11:45 a.m. ET CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a [...]

Pages